

## MID AND SOUTH ESSEX MEDICINES OPTIMISATION COMMITTEE (MSEMOC)

### OMALIZUMAB FOR TREATING CHRONIC RHINOSINUSITIS WITH NASAL POLYPS, NICE TA678, FEBRUARY 2021 (TERMINATED APPRAISAL)

**BLACK: NOT RECOMMENDED FOR PRESCRIBING IN PRIMARY, COMMUNITY OR  
SECONDARY CARE**

Mid and South Essex CCGs do not support the prescribing of omalizumab for treating chronic rhinosinusitis with nasal polyps in accordance with local recommendations for all drugs with a terminated NICE technology appraisal.

[NICE TA678](#) guidance:

NICE is unable to make a recommendation on omalizumab (Xolair®) for treating chronic rhinosinusitis with nasal polyps in adults because Novartis Pharmaceuticals did not provide an evidence submission. NICE will review this decision if the company decides to make a submission.

Providers commissioned to provide services on behalf of Mid and South Essex CCGs are reminded that they are required to follow the local joint formulary and prescribing guidance, as detailed in the medicines management service specification of their contract.

<b>References</b>	NICE TA678: Omalizumab for treating chronic rhinosinusitis with nasal polyps: <a href="https://www.nice.org.uk/guidance/ta678">https://www.nice.org.uk/guidance/ta678</a>
<b>Acknowledgements</b>	Mid and South Essex CCGs Medicines Management Teams
<b>Version</b>	1.0
<b>Author</b>	HCPMSEMOC working group
<b>Approved by</b>	MSEMOC; MSE Joint Committee
<b>Date Approved</b>	May 2021; May 2021
<b>Review Date</b>	May 2026 or sooner if subject to any new updates nationally